section,entity_id,entity_name,entity_name_en,entity_type,category,attribute_path,value,evidence_source
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,name_en,Osteoporosis,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,description,以骨量减少、骨组织微结构破坏为特征的全身性骨病,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,icd_10,M80-M81,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.prevalence_postmenopausal,50岁以上女性19.2%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.prevalence_elderly_men,65岁以上男性13.0%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.fracture_risk,髋部骨折终生风险女性13%，男性4%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.economic_burden,年医疗费用超过190亿元,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.type,I型骨质疏松,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.mechanism,雌激素缺乏,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.onset,绝经后5-10年,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.bone_loss_rate,每年2-5%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.type,II型骨质疏松,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.mechanism,年龄相关骨丢失,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.onset,70岁以后,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.characteristics,皮质骨和松质骨均受累,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.secondary.endocrine,甲状腺功能亢进; 甲状旁腺功能亢进; 库欣综合征; 性腺功能减退,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.secondary.medications,糖皮质激素; 抗癫痫药物; 芳香化酶抑制剂; GnRH激动剂,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.secondary.diseases,类风湿关节炎; 炎症性肠病; 慢性肾病; 恶性肿瘤,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.bone_remodeling_imbalance.normal_remodeling,骨形成与骨吸收平衡,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.bone_remodeling_imbalance.osteoporosis,骨吸收 > 骨形成,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.bone_remodeling_imbalance.cellular_mechanism,破骨细胞活性增加，成骨细胞功能减退,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.hormonal_factors.estrogen_deficiency,雌激素缺乏导致RANKL/OPG比值升高,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.hormonal_factors.pth_excess,继发性甲旁亢加速骨丢失,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.hormonal_factors.vitamin_d_deficiency,影响钙吸收和骨矿化,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mechanical_factors.disuse,缺乏负重运动,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mechanical_factors.immobilization,长期卧床,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mechanical_factors.microgravity,失重环境,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.asymptomatic_phase.duration,数年至数十年,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.asymptomatic_phase.characteristics,无症状骨量丢失,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.asymptomatic_phase.detection,仅通过骨密度检测发现,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.bone_pain.location,腰背部最常见,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.bone_pain.characteristics,持续性钝痛,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.bone_pain.aggravating_factors,活动后加重,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.vertebral.prevalence,最常见骨折类型,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.vertebral.symptoms,急性背痛，身高缩短,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.vertebral.complications,脊柱畸形，肺功能受损,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.hip.mortality,1年死亡率15-20%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.hip.morbidity,50%患者不能独立行走,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.hip.economic_impact,医疗费用最高,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.distal_radius.onset,绝经早期常见,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.distal_radius.mechanism,跌倒时手掌撑地,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.distal_radius.recovery,相对较好,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.kyphosis.cause,椎体压缩性骨折,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.kyphosis.appearance,驼背畸形,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.kyphosis.functional_impact,呼吸功能受限,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.gold_standard,双能X线吸收测定法,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.sites,腰椎L1-L4; 股骨颈; 全髋,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.normal,T评分 ≥ -1.0,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.osteopenia,T评分 -1.0 到 -2.5,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.osteoporosis,T评分 ≤ -2.5,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.severe_osteoporosis,T评分 ≤ -2.5 + 脆性骨折,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.qct.method,定量CT,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.qct.advantage,真正的体积骨密度,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.qct.limitation,辐射剂量较高,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.peripheral_devices.pdexa,外周双能X线,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.peripheral_devices.qus,定量超声,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.peripheral_devices.use,筛查工具,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_formation.osteocalcin,骨钙素,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_formation.p1np,I型前胶原氨基端肽,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_formation.balp,骨特异性碱性磷酸酶,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_resorption.ctx,I型胶原羧基端肽,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_resorption.ntx,I型胶原氨基端肽,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_resorption.trap_5b,抗酒石酸酸性磷酸酶5b,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.clinical_utility,监测治疗反应; 评估骨转换状态; 预测骨折风险,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.frax_tool.components,年龄、性别、BMI; 既往骨折史; 父母髋部骨折史; 吸烟、饮酒; 糖皮质激素使用; 类风湿关节炎; 继发性骨质疏松原因; 股骨颈骨密度,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.frax_tool.output,10年髋部骨折和主要骨折风险,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.qfracture,英国骨折风险评估工具,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.garvan,澳大利亚骨折风险计算器,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.calcium,每日1000-1200mg,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.vitamin_d,800-1000IU/日,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.protein,每日1.0-1.2g/kg体重,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.limitations,避免过量咖啡因、钠盐,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.weight_bearing,负重有氧运动,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.resistance_training,阻力训练,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.balance_training,平衡训练预防跌倒,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.frequency,每周至少3-4次,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.environmental,移除家中危险因素,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.vision_correction,视力矫正,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.medication_review,评估致跌倒药物,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.assistive_devices,使用辅助器具,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.alendronate.dose,阿仑膦酸钠 70mg/周,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.alendronate.administration,空腹服用，服后直立30分钟,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.alendronate.efficacy,椎体骨折风险降低40-50%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.risedronate.dose,利塞膦酸钠 35mg/周,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.risedronate.advantage,胃肠道耐受性好,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.risedronate.efficacy,髋部骨折风险降低30%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.ibandronate.dose,伊班膦酸钠 150mg/月,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.ibandronate.route,口服或静脉注射,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.ibandronate.convenience,给药频率低,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.zoledronic_acid.dose,唑来膦酸 5mg/年,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.zoledronic_acid.route,静脉滴注,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.zoledronic_acid.efficacy,最强的抗骨折效果,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.mechanism,RANKL抗体,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.dose,地诺单抗 60mg/6个月 皮下注射,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.efficacy,椎体骨折风险降低68%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.consideration,停药后骨量快速丢失,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.mechanism,重组PTH(1-34),Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.dose,特立帕肽 20μg/日 皮下注射,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.duration,最多2年,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.indication,严重骨质疏松症,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.abaloparatide.mechanism,PTHrP类似物,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.abaloparatide.dose,阿巴洛帕肽 80μg/日,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.abaloparatide.advantage,较少高钙血症风险,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.postmenopausal.estrogen,雌激素替代治疗,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.postmenopausal.indication,绝经期症状明显,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.postmenopausal.risks,血栓、乳腺癌风险,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.selective_modulators.raloxifene,雷洛昔芬 60mg/日,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.selective_modulators.benefit,预防椎体骨折和乳腺癌,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.selective_modulators.limitation,不预防髋部骨折,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.bone_density,治疗后1-2年复查DXA,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.biochemical_markers,治疗后3-6个月检测,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.clinical_assessment,定期评估疼痛和功能,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.safety_monitoring,监测药物不良反应,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.fracture_complications.vertebral,慢性疼痛; 脊柱畸形; 功能障碍,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.fracture_complications.hip,深静脉血栓; 肺栓塞; 死亡,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.fracture_complications.general,感染; 褥疮; 肌肉萎缩,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.medication_related.bisphosphonates,上消化道刺激; 下颌骨坏死(罕见); 非典型股骨骨折(极罕见),Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.medication_related.denosumab,低钙血症; 感染风险增加; 停药后骨折风险反弹,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.with_treatment,骨折风险显著降低,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.fracture_healing,愈合能力基本正常,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.quality_of_life,疼痛减轻，功能改善,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.life_expectancy,早期诊断治疗预后良好,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,name_en,Osteomalacia,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,description,成人维生素D缺乏或代谢异常导致的骨矿化障碍,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,icd_10,M83,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.prevalence,维生素D缺乏患者中10-15%,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.risk_populations,老年人群; 日照不足地区; 室内工作者; 穿着遮体服装人群,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.geographic_distribution,高纬度地区高发,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.inadequate_sunlight,日照不足,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.dietary_insufficiency,膳食摄入不足,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.malabsorption,吸收不良综合征,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.chronic_kidney_disease,慢性肾病,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_metabolism_disorders.1_alpha_hydroxylase_deficiency,1α-羟化酶缺陷,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_metabolism_disorders.vitamin_d_receptor_defects,维生素D受体缺陷,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_metabolism_disorders.24_hydroxylase_excess,24-羟化酶过度活跃,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.phosphate_deficiency.hereditary_hypophosphatemia,遗传性低磷血症,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.phosphate_deficiency.tumor_induced,肿瘤诱发性骨软化症,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.phosphate_deficiency.fanconi_syndrome,Fanconi综合征,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.drug_induced,抗癫痫药物; 糖皮质激素; 铝制剂; 氟化物过量,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mineralization_defect.mechanism,骨基质正常，矿化不足,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mineralization_defect.histology,增宽的骨样组织缝,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mineralization_defect.biochemistry,钙磷乘积不足,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.secondary_hyperparathyroidism.trigger,低钙血症或维生素D缺乏,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.secondary_hyperparathyroidism.consequences,PTH升高，骨转换增加,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.secondary_hyperparathyroidism.bone_effects,骨吸收增加,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.muscle_effects.weakness,近端肌无力,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.muscle_effects.mechanism,维生素D受体缺陷,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.muscle_effects.recovery,补充维生素D后改善,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.bone_pain.characteristics,弥漫性钝痛,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.bone_pain.location,腰背部、髋部、胸肋部,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.bone_pain.timing,休息时也存在,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.tenderness,骨压痛，尤其是胸骨,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.fractures,假性骨折(Looser带),Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.deformities,严重时出现骨骼变形,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.proximal_weakness,近端肌群无力,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.myalgia,肌肉疼痛,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.difficulty_walking,行走困难,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.falls,跌倒风险增加,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.fatigue,疲劳乏力,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.depression,抑郁情绪,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.cognitive_impairment,认知功能下降,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.increased_infections,感染易感性增加,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.vitamin_d_status.25_oh_d3,<30nmol/L (严重缺乏),Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.vitamin_d_status.1_25_oh2_d3,可正常或降低,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.vitamin_d_status.optimal_level,25(OH)D3 >75nmol/L,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.calcium_phosphate.serum_calcium,正常或轻度降低,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.calcium_phosphate.serum_phosphate,正常或降低,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.calcium_phosphate.ionized_calcium,可能降低,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.parathyroid_function.pth,升高(继发性甲旁亢),Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.parathyroid_function.correlation,与25(OH)D3水平负相关,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.bone_turnover_markers.alkaline_phosphatase,升高,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.bone_turnover_markers.osteocalcin,可升高,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.bone_turnover_markers.ctx,可升高,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.x_ray.pseudofractures,Looser带(假性骨折线),Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.x_ray.common_sites,股骨颈; 耻骨支; 肋骨,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.x_ray.osteopenia,弥漫性骨量减少,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_scan.hotspots,Looser带处放射性摄取增加,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_scan.pattern,多发性热点,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_biopsy.indication,诊断困难时,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_biopsy.findings,增宽的骨样组织缝,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_biopsy.gold_standard,确诊的金标准,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.cholecalciferol.loading_dose,"维生素D3 50,000IU/周 × 8周",Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.cholecalciferol.maintenance,800-2000IU/日,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.cholecalciferol.monitoring,治疗后6-8周检测25(OH)D3,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.ergocalciferol.dose,"维生素D2 50,000IU/周",Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.ergocalciferol.efficacy,较维生素D3稍差,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.active_metabolites.calcitriol,骨化三醇 0.25-1μg/日,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.active_metabolites.alfacalcidol,阿法骨化醇 0.5-2μg/日,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.active_metabolites.indication,肾功能不全患者,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.calcium_supplementation.elemental_calcium,1000-1500mg/日,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.calcium_supplementation.timing,与维生素D同服,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.calcium_supplementation.monitoring,避免过量补充,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.phosphate_supplementation.indication,低磷血症患者,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.phosphate_supplementation.dose,磷酸盐 1-3g/日 分次服用,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.phosphate_supplementation.monitoring,血磷、PTH水平,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.sun_exposure,增加日光照射,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.dietary_modification,富含维生素D食物,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.physical_therapy,肌力训练,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.fall_prevention,预防跌倒措施,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,monitoring.biochemical,25(OH)D3 每3-6个月; 血钙、磷、PTH; 肾功能; 骨转换标志物,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,monitoring.clinical,疼痛评估; 肌力测试; 步态分析; 跌倒风险评估,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,monitoring.imaging,骨密度(DXA); 必要时重复X线检查,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.with_treatment,症状明显改善,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.bone_healing,假性骨折可愈合,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.muscle_recovery,肌无力逐渐恢复,Endocrine Society Growth Hormone Guidelines 2024
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.prevention,适当补充可完全预防,Endocrine Society Growth Hormone Guidelines 2024
